vs

Side-by-side financial comparison of Canaan Inc. (CAN) and Connect Biopharma Holdings Ltd (CNTB). Click either name above to swap in a different company.

Connect Biopharma Holdings Ltd is the larger business by last-quarter revenue ($24.1M vs $20.8M, roughly 1.2× Canaan Inc.). Connect Biopharma Holdings Ltd runs the higher net margin — 61.6% vs -18.4%, a 80.0% gap on every dollar of revenue.

Canaan Inc., doing business as Canaan Creative and known simply as Canaan, is a Singapore-based computer hardware manufacturer. Established in 2013 by N.G. Zhang, Canaan specializes in Blockchain servers and ASIC microprocessors for use in bitcoin mining.

Connect Biopharma Holdings Ltd is a clinical-stage global biopharmaceutical company dedicated to developing innovative targeted therapies for inflammatory, immunological and autoimmune diseases. Its core pipeline includes candidate treatments for asthma, atopic dermatitis and other conditions with high unmet medical needs, with main operations across the U.S., China and key global markets to deliver effective therapeutic solutions to patients.

CAN vs CNTB — Head-to-Head

Bigger by revenue
CNTB
CNTB
1.2× larger
CNTB
$24.1M
$20.8M
CAN
Higher net margin
CNTB
CNTB
80.0% more per $
CNTB
61.6%
-18.4%
CAN

Income Statement — Q3 FY2025 vs Q2 FY2024

Metric
CAN
CAN
CNTB
CNTB
Revenue
$20.8M
$24.1M
Net Profit
$-3.8M
$14.8M
Gross Margin
99.9%
Operating Margin
-15.9%
56.6%
Net Margin
-18.4%
61.6%
Revenue YoY
Net Profit YoY
148.7%
EPS (diluted)
$-0.05
$0.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CAN
CAN
CNTB
CNTB
Q4 25
$20.8M
Q3 25
$13.8M
Q2 25
$11.4M
Q3 24
$10.2M
Q2 24
$4.8M
$24.1M
Q2 23
$0
Net Profit
CAN
CAN
CNTB
CNTB
Q4 25
$-3.8M
Q3 25
$-1.5M
Q2 25
$-11.9M
Q3 24
$-10.4M
Q2 24
$-5.4M
$14.8M
Q2 23
$-30.5M
Gross Margin
CAN
CAN
CNTB
CNTB
Q4 25
99.9%
Q3 25
99.9%
Q2 25
99.9%
Q3 24
99.9%
Q2 24
99.8%
Q2 23
Operating Margin
CAN
CAN
CNTB
CNTB
Q4 25
-15.9%
Q3 25
-27.0%
Q2 25
-45.5%
Q3 24
-77.2%
Q2 24
-193.9%
56.6%
Q2 23
Net Margin
CAN
CAN
CNTB
CNTB
Q4 25
-18.4%
Q3 25
-11.0%
Q2 25
-104.4%
Q3 24
-102.7%
Q2 24
-112.3%
61.6%
Q2 23
EPS (diluted)
CAN
CAN
CNTB
CNTB
Q4 25
$-0.05
Q3 25
$-0.02
Q2 25
$-0.25
Q3 24
Q2 24
$0.27
Q2 23
$-0.55

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CAN
CAN
CNTB
CNTB
Cash + ST InvestmentsLiquidity on hand
$110.2M
Total DebtLower is stronger
$6.2M
Stockholders' EquityBook value
$52.4M
$110.9M
Total Assets
$92.5M
$120.6M
Debt / EquityLower = less leverage
0.12×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CAN
CAN
CNTB
CNTB
Q4 25
Q3 25
Q2 25
Q3 24
Q2 24
$110.2M
Q2 23
$81.6M
Total Debt
CAN
CAN
CNTB
CNTB
Q4 25
$6.2M
Q3 25
$6.2M
Q2 25
$6.2M
Q3 24
Q2 24
Q2 23
Stockholders' Equity
CAN
CAN
CNTB
CNTB
Q4 25
$52.4M
Q3 25
$44.7M
Q2 25
$33.8M
Q3 24
$43.6M
Q2 24
$56.8M
$110.9M
Q2 23
$128.7M
Total Assets
CAN
CAN
CNTB
CNTB
Q4 25
$92.5M
Q3 25
$81.7M
Q2 25
$78.0M
Q3 24
$69.3M
Q2 24
$73.7M
$120.6M
Q2 23
$144.1M
Debt / Equity
CAN
CAN
CNTB
CNTB
Q4 25
0.12×
Q3 25
0.14×
Q2 25
0.18×
Q3 24
Q2 24
Q2 23

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CAN
CAN
CNTB
CNTB
Operating Cash FlowLast quarter
$-8.0M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
-0.54×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CAN
CAN
CNTB
CNTB
Q4 25
Q3 25
Q2 25
Q3 24
Q2 24
$-8.0M
Q2 23
$-31.2M
Cash Conversion
CAN
CAN
CNTB
CNTB
Q4 25
Q3 25
Q2 25
Q3 24
Q2 24
-0.54×
Q2 23

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons